• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 1:15:57 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LTRN alert in real time by email
    SC 13G 1 tm216774d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Amendment #

     

    LANTERN PHARMA Inc.
    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

     

    51654W101
    (CUSIP Number)

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 51654W101
    (1)

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

    Arunkumar Asaithambi

    (2)

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    N/A

    (3)

    SEC Use Only

     

    (4)

    Citizenship or Place of Organization

     

    India

    Numbers of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5)

    Sole Voting Power

     

    470,460

    (6)

    Shared Voting Power

     

    0

    (7)

    Sole Dispositive Power

     

    470,460

    (8)

    Shared Dispositive Power

     

    0

    (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    470,460

    (10)

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ¨

     

    Not applicable.

    (11)

    Percent of Class Represented by Amount in Row (9)

     

    4.5%

    (12)

    Type of Reporting Person (See Instructions)

     

    IN

     

    Page 2 of 5

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Lantern Pharma Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    1920 McKinney Ave.

    7th Floor
    Dallas, TX 75201

     

    Item 2.

     

    (a)Name of Person Filing

     

    Arunkumar Asaithambi

     

    (b)Address of Principal Business Office or, if none, Residence

     

    3 Pleasant Lane, Oyster Bay, NY 11771

     

    (c)Citizenship

     

    India

     

    (d)Title of Class of Securities

     

    Lantern Pharma Inc. common stock $0.0001 par value per share

     

    (e)CUSIP Number

     

    51654W101

     

    Item 3.

     

    Not Applicable.

     

    Item 4.

     

    The stock ownership information below is presented as of the date hereof, which consists of 426,960 shares of common stock held by the reporting person and 43,500 shares of common stock which may be acquired pursuant to an option arrangement. The percentage set forth below is based on 10,503,292 shares of Common Stock issued and outstanding as of January 20, 2021, as represented in the Company’s Prospectus filed with the Securities and Exchange Commission on January 15, 2021 (the “January Prospectus”), plus 43,500 shares issuable upon the exercise of outstanding options. As of December 31, 2020, the reporting person’s stock ownership consisted of 441,960 shares of common stock held by the reporting person and 43,500 shares of common stock which may be acquired pursuant to an option arrangement. The shares of common stock constituted 7.7% of the Company’s outstanding common stock based on 6,220,927 shares outstanding as of November 6, 2020 as reported in the January Prospectus, plus 43,500 shares issuable upon the exercise of outstanding options. As of the date hereof, the Company had completed the public offering contemplated by the January Prospectus, resulting in the percentage ownership set forth below.

     

    (a)Amount beneficially owned:

     

    470,460

     

    Page 3 of 5

     

     

    (b)Percent of class:

     

    4.5%

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote

     

    470,460

     

    (ii)Shared power to vote or to direct the vote

     

    0

     

    (iii)Sole power to dispose or to direct the disposition of

     

    470,460

     

    (iv)Shared power to dispose or to direct the disposition of

     

    0

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    Not applicable.

     

    Page 4 of 5

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 12, 2021 By: /s/ Arunkumar Asaithambi
        Name: Arunkumar Asaithambi

     

    Page 5 of 5

     

    Get the next $LTRN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LTRN

    DatePrice TargetRatingAnalyst
    3/11/2022$34.00 → $36.00Buy
    HC Wainwright & Co.
    11/2/2021$32.00 → $34.00Buy
    HC Wainwright & Co.
    10/7/2021$32.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LTRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Schalop Lee Troy

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    8/20/25 6:25:16 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Schalop Lee Troy

    3 - Lantern Pharma Inc. (0001763950) (Issuer)

    7/30/25 5:20:47 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Fletcher Aaron G.L. sold $123,600 worth of shares (40,000 units at $3.09) (SEC Form 4)

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    6/13/25 7:57:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $36.00 from $34.00 previously

    3/11/22 6:29:59 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $34.00 from $32.00 previously

    11/2/21 6:34:51 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. initiated coverage of Lantern Pharma with a rating of Buy and set a new price target of $32.00

    10/7/21 8:16:17 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

    Major milestone achieved with successful completion of enrollment for LP-184 Phase 1a clinical trial, with 65 patients enrolled across a range of solid tumors including glioblastoma (GBM); LP-184 is a potential blockbuster drug-candidate with market potential of $10-12 billion USD in annual revenue. Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) established for LP-184, enabling advancement to upcoming Phase 1b/2 trials being planned for recurrent triple negative breast cancer (TNBC) and recurrent bladder cancer. Remarkable complete response observed in HARMONIC™ Trial patient: A 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) demonstrated a co

    8/13/25 4:30:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

    Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progression GBM represents an annual market opportunity of $3 to $5 billion USD with an accelerating number of cases globally Lantern Pharma has previously received both FDA Orphan and Fast Track Designations in GBM Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. (NASDAQ:LTRN), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase Ib/2a clinical trial to evaluate STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (GBM) at

    8/6/25 8:30:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

    Industry-Leading Platform Achieves 94% Accuracy with Real-Time Machine Learning, Providing Open-Access to Critical CNS Drug Development Technology Additional Predictive, Analytic and Descriptive Modules are Planned for Release Leveraging Lantern's Large-Scale Molecular Features Data Lake and Proprietary Ensemble Algorithmic Approach Lantern Pharma Inc. (NASDAQ:LTRN), a pioneering artificial intelligence company transforming oncology drug discovery and development, today announced the public release of its AI module for predicting blood-brain barrier (BBB) permeability of small molecules with unprecedented accuracy and scalability – predictBBB.ai™. This critical advancement addresses

    8/4/25 8:55:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    SEC Filings

    View All

    Lantern Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lantern Pharma Inc. (0001763950) (Filer)

    8/13/25 4:15:50 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lantern Pharma Inc.

    10-Q - Lantern Pharma Inc. (0001763950) (Filer)

    8/13/25 4:06:50 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Lantern Pharma Inc.

    DEF 14A - Lantern Pharma Inc. (0001763950) (Filer)

    8/8/25 5:17:38 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Financials

    Live finance-specific insights

    View All

    Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

    Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer (NSCLC) anticipated in Q3 2025, including initial readout for patients from the Asian expansion cohort. Strengthened AI intellectual property portfolio with PCT publication of proprietary blood-brain barrier penetration prediction patent application; favorable PCT search report indicated no significant prior art. Expanded RADR® platform with innovative AI-powered module to improve the precision, cost and timeline of antibody

    5/15/25 8:45:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

    Webcast to be held Thursday, May 15th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2025 operating and financial results webcast on Thursday, May 15, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the first quarter ended March 31, 2025 and provide guidance on upcoming milestones, clinical tria

    5/8/25 8:30:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

    HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

    3/27/25 4:01:00 PM ET
    $ACTU
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

    SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

    3/1/24 4:10:40 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lantern Pharma Inc. (Amendment)

    SC 13G/A - Lantern Pharma Inc. (0001763950) (Subject)

    2/14/24 4:05:49 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

    SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

    12/1/23 6:02:25 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Leadership Updates

    Live Leadership Updates

    View All

    Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

    Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member

    7/28/25 8:00:00 AM ET
    $CMRX
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

    DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manag

    9/2/21 8:59:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care